BIOMAT Database Logo BIOMAT Database Logo

Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. 2007

Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Department of Urology, University Clinics of Brussels, Erasme Hospital, Brussels, Belgium. Claude.Schulman@ulb.ac.be

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008297 Male Males
D011364 Professional Practice The use of one's knowledge in a particular profession. It includes, in the case of the field of biomedicine, professional activities related to health care and the actual performance of the duties related to the provision of health care. Practice, Professional,Practices, Professional,Professional Practices
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013739 Testosterone A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL. 17-beta-Hydroxy-4-Androsten-3-one,17-beta-Hydroxy-8 alpha-4-Androsten-3-one,8-Isotestosterone,AndroGel,Androderm,Andropatch,Androtop,Histerone,Sterotate,Sustanon,Testim,Testoderm,Testolin,Testopel,Testosterone Sulfate,17 beta Hydroxy 4 Androsten 3 one,17 beta Hydroxy 8 alpha 4 Androsten 3 one,8 Isotestosterone
D016729 Leuprolide A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. Leuprorelin,A-43818,Enantone,Leuprolide Acetate,Leuprolide Monoacetate,Leuprolide, (DL-Leu)-Isomer,Leuprolide, (L-Leu)-Isomer,Lupron,TAP-144,A 43818,A43818,Acetate, Leuprolide,Monoacetate, Leuprolide,TAP 144,TAP144
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D018931 Antineoplastic Agents, Hormonal Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) Hormonal Antineoplastic Agents,Antineoplastic Drugs, Hormonal,Antineoplastic Hormonal Agents,Antineoplastic Hormonal Drugs,Antineoplastics, Hormonal,Hormonal Agents, Antineoplastic,Hormonal Antineoplastic Drugs,Hormonal Antineoplastics,Agents, Antineoplastic Hormonal,Drugs, Antineoplastic Hormonal,Hormonal Drugs, Antineoplastic

Related Publications

Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
March 1989, Acta endocrinologica,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist.
November 1993, Urology,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
June 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
July 2002, The Journal of urology,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
January 1991, DICP : the annals of pharmacotherapy,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Acute Progression of Recurrent Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer.
July 2016, World neurosurgery,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Auricular acupuncture: a novel treatment for vasomotor symptoms associated with luteinizing-hormone releasing hormone agonist treatment for prostate cancer.
January 2009, BJU international,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Luteinizing hormone-releasing hormone agonist monotherapy for prostate cancer: outcome and prognostic factors.
April 2005, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
July 1987, Fertility and sterility,
Claude Schulman, and Antonio Alcaraz, and Richard Berges, and Francesco Montorsi, and Pierre Teillac, and Bertrand Tombal
Progression of intracranial meningioma during luteinizing hormone-releasing hormone agonist treatment for prostate cancer: case report.
January 2014, Neurologia medico-chirurgica,
Copied contents to your clipboard!